Explain this page
Arphra AIPlain-English read on Pfizer Inc.’s valuationAI Issuer Brief
Arphra AILoading cached brief…
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.06% | -2.03% | -2.62% | -5.94% | +1.95% | +2.97% | +9.29% | -33.16% | -33.90% | -22.42% | +5869.32% |
Aftermarket
LiveLast trade
$25.61
840 sh
Bid
$25.60
465 sh
Ask
$25.63
18 sh
Spread
$0.030
Sector & industry today
LiveSectors
- Technology+3.30%
- Basic Materials+0.98%
- Energy+0.83%
- Consumer Cyclical+0.49%
- Industrials+0.25%
- Communication Services+0.13%
- Healthcare-0.65%
- Financial Services-0.80%
- Consumer Defensive-0.84%
- Utilities-1.15%
- Real Estate-1.32%
Top industries (issuer's industry highlighted)
- Drug Manufacturers - General-1.11%
- Computer Hardware+8.35%
- Software - Infrastructure+7.61%
- Consulting Services+5.28%
- Coal+5.20%
- Manufacturing - Metal Fabrication+4.24%
- Staffing & Employment Services+4.08%
- Gambling, Resorts & Casinos+3.71%
- Broadcasting+3.70%
- Integrated Freight & Logistics+3.68%
- REIT - Healthcare Facilities-3.49%
- Software - Application+3.44%
Fair value
Football field →Weighted blend
$74.42
+190.24% vs spot
Recommendation
Strong Buy
18 of 19 methods
Method spread
14bull3bear
±5% threshold
Analyst PT consensus: $27.27 (+6.36%)
Total assets
$208.16B
Total debt
$67.42B
Cash & equiv
$1.14B
Operating CF
$11.71B
Free cash flow
$9.08B
Buybacks
$0
Analyst view
DB · price_targets + analyst_gradesConsensus target
$27.27
+6.36% upside
Low
$24.00
Median
$27.00
High
$35.00
Recent actions
0 ↑0 ↓8 hold
- Apr 01, 2026
- Mar 01, 2026
- Feb 01, 2026
- Jan 01, 2026
- Dec 01, 2025
News
DB · news_items- Can Pfizer Achieve High Single-Digit Revenue CAGR From 2029?zacks.com·May 13, 2026
- European Commission Approves Pfizer's HYMPAVZI for the Treatment of Adults and Adolescents with Hemophilia A or B With Inhibitorsbusinesswire.com·May 13, 2026
- European Commission Approves Pfizer's HYMPAVZI for the Treatment of Adults and Adolescents with Hemophilia A or B With Inhibitorsbusinesswire.com·May 13, 2026
- Pfizer: Don't Pass On This Dirt-Cheap Buying Opportunityseekingalpha.com·May 12, 2026
- Prediction: Pfizer Will Beat the Market Over the Next 5 Yearsfool.com·May 12, 2026
- Rigel strikes licensing deal for Pfizer and Arvinas' breast cancer drugreuters.com·May 12, 2026
- Is Pfizer a Buy, Sell, or Hold in 2026?fool.com·May 12, 2026
- Pfizer's Net Income Drops in Q1. Is Its Dividend Still Safe?fool.com·May 12, 2026
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q4 Dec 2025 | $17.56B | -$1.65B | $-0.29 |
| Q3 Sep 2025 | $16.65B | $3.54B | $0.62 |
| Q2 Jun 2025 | $14.65B | $2.91B | $0.51 |
| Q1 Mar 2025 | $13.72B | $2.97B | $0.52 |
| Q4 Dec 2024 | $17.76B | $403M | $0.07 |
| Q3 Sep 2024 | $17.7B | $4.47B | $0.78 |
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
DAMICO JENNIFER B. officer: SVP & Controller | Sell | 2,500 | $64.83K | Mar 04, 2025 |
BLAYLOCK RONALD E director | Buy | 19,457 | $499.07K | Feb 13, 2025 |
Gottlieb Scott director | Buy | 1,000 | $28.24K | Oct 30, 2024 |
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|---|---|---|---|---|
| FY 2025 | $62.58B | $15.44B | $7.77B | $1.36 | +12.42% |
| FY 2024 | $63.63B | $16.48B | $8.02B | $1.41 | +12.60% |
| FY 2023 | $59.55B | $5.29B | $2.13B | $0.37 | +3.58% |
| FY 2022 | $100.33B | $37.55B | $31.37B | $5.47 | +31.26% |
| FY 2021 | $81.29B | $20.79B | $22.15B | $3.88 | +27.25% |